耐药及高危恶性滋养细胞肿瘤20例临床分析  

The clinic analysis of resistant and high-risk malignant gestational trophoblastic tumor in 20 cases

作　　者：郭兴来 梅新宽 钱和生[1] 史洪武[1] 亓兵[1] 

机构地区：[1]阜阳市肿瘤医院肿瘤内科,236022

出　　处：《安徽医学》2011年第10期1726-1728,共3页Anhui Medical Journal

摘　　要：目的观察EMA/CO方案治疗耐药及高危妊娠恶性滋养细胞肿瘤的疗效及毒副反应。方法 2007年2月至2010年2月,采用EMA/CO方案治疗耐药及高危妊娠恶性滋养细胞肿瘤20例,其中初治患者18例,耐药患者1例,复发患者1例。结果该方案治疗20例妊娠恶性滋养细胞肿瘤患者,16例完全缓解,总完全缓解率为80%。其中,侵蚀性葡萄胎的完全缓解率为88.89%,绒癌为72.73%,初治性妊娠恶性滋养细胞肿瘤为88.89%。毒副反应主要为I-II度恶心、呕吐和骨髓抑制。结论EMA/CO方案是治疗耐药和高危滋养细胞肿瘤的有效方案,疗效好,毒副反应较轻,可以作为首选方案,患者易接受,值得临床推广。Objective Observation of EMA / CO regimen in the treatment resistant and high-risk malignant gestational trophoblastic tumor efficacy and toxicity.Methods February 2007 to February 2010,with EMA / CO regimen in the treatment resistant and high-risk malignant gestational trophoblastic tumor in 20 cases,of which 18 cases of newly diagnosed patients,patients with drug resistance in 1 case,1 case of recurrent patients.Results The 20 patients in the treatment of malignant gestational trophoblastic tumor patients,16 had complete remission,complete remission rate of 80% of the total.Including invasive mole in the complete remission rate of 88.89%,choriocarcinoma of the complete remission rate of 72.73%,initial treatment of malignant gestational trophoblastic tumor complete remission rate of 88.89%.The major side effect is I-II nausea,vomiting and bone marrow suppression.Conclusion EMA / CO treatment program is a high-risk gestational trophoblastic tumor resistant and effective program,good efficacy,less side effects,can serve as a preferred option,easily accepted by patients,deserves further study.

关 键 词：妊娠 恶性滋养细胞肿瘤 化疗 

分 类 号：R737.33[医药卫生—肿瘤]